Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds B of A Securities Reinstates Neutral on Gilead Sciences, Announces $85 Price Target

B of A Securities Reinstates Neutral on Gilead Sciences, Announces $85 Price Target

B of A Securities analyst Geoff Meacham reinstates Gilead Sciences (NASDAQ:GILD) with a Neutral and announces $85 price target.

byBenzinga Newsdesk

December 13, 2022

1 minute read

B of A Securities analyst Geoff Meacham reinstates Gilead Sciences (NASDAQ:GILD) with a Neutral and announces $85 price target.

Analyst Ratings

Analyst Expectations for AG Mortgage IT’s Future

By Benzinga Insights

July 21, 8:00 AM

Analysts have provided the following ratings for AG Mortgage IT (NYSE:MITT) within the last quarter: Bullish Somewhat Bullish…

MITT

Raymond James Maintains Strong Buy on Acadia Healthcare Co, Raises Price Target to $100

By Benzinga Newsdesk

August 1, 4:52 AM

Raymond James analyst John Ransom maintains Acadia Healthcare Co (NASDAQ:ACHC) with a Strong Buy and raises the price target from $85 to $100.

ACHC

What’s Going On With T2 Biosystems (TTOO) Stock?

By Erica Kollmann

August 16, 12:54 PM

T2 Biosystems, Inc. (NASDAQ: TTOO) shares are volatile Wednesday.

TTOO

Numinus Wellness Announces Q3 Results

By Lara Goldstein

July 15, 6:06 PM

Mental healthcare company advancing psychedelic-assisted therapies Numinus Wellness Inc. (OTCQX: NUMIF) recently announced its fiscal quarter results for the three and nine months ended May 31, 2022.

NUMIF

B of A Securities Reinstates Neutral on Gilead Sciences, Announces $85 Price Target

Related Posts

Analyst Expectations for AG Mortgage IT’s Future

Raymond James Maintains Strong Buy on Acadia Healthcare Co, Raises Price Target to $100

What’s Going On With T2 Biosystems (TTOO) Stock?

Numinus Wellness Announces Q3 Results